Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

OBJECTIVES: Ischaemic digital ulcers (DUs) are common in patients with systemic sclerosis (SSc) and are a cause of disease-related morbidity. In an earlier trial, treatment with bosentan, an oral endothelin receptor antagonist, reduced the occurrence of new DUs by 48%. The present study (RAPIDS-2, f...

Descripción completa

Detalles Bibliográficos
Autores principales: Matucci-Cerinic, Marco, Denton, Christopher P, Furst, Daniel E, Mayes, Maureen D, Hsu, Vivien M, Carpentier, Patrick, Wigley, Fredrick M, Black, Carol M, Fessler, Barri J, Merkel, Peter A, Pope, Janet E, Sweiss, Nadera J, Doyle, Mittie K, Hellmich, Bernhard, Medsger, Thomas A, Morganti, Adele, Kramer, Fabrice, Korn, Joseph H, Seibold, James R
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2010
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002766/
https://www.ncbi.nlm.nih.gov/pubmed/20805294
http://dx.doi.org/10.1136/ard.2010.130658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002766/
https://www.ncbi.nlm.nih.gov/pubmed/20805294
http://dx.doi.org/10.1136/ard.2010.130658

Ejemplares similares